Cryopraxis

Migration, Crosslink

📖

Cryopraxis

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-cryopraxis

📖 Wiki Page

company1531 wordssynced 2026-04-02

Overview

flowchart TD companies_cryopraxis["Cryopraxis"] style companies_cryopraxis fill:#4fc3f7,stroke:#333,color:#000 companies_cryopraxis_0["Corporate Profile"] companies_cryopraxis -->|"includes"| companies_cryopraxis_0 style companies_cryopraxis_0 fill:#81c784,stroke:#333,color:#000 companies_cryopraxis_1["Company History"] companies_cryopraxis -->|"includes"| companies_cryopraxis_1 style companies_cryopraxis_1 fill:#ef5350,stroke:#333,color:#000 companies_cryopraxis_2["Neurodegeneration Focus"] companies_cryopraxis -->|"includes"| companies_cryopraxis_2 style companies_cryopraxis_2 fill:#ffd54f,stroke:#333,color:#000 companies_cryopraxis_3["Parkinsons Disease"] companies_cryopraxis -->|"includes"| companies_cryopraxis_3 style companies_cryopraxis_3 fill:#ce93d8,stroke:#333,color:#000 companies_cryopraxis_4["Alzheimers Disease"] companies_cryopraxis -->|"includes"| companies_cryopraxis_4 style companies_cryopraxis_4 fill:#4fc3f7,stroke:#333,color:#000 companies_cryopraxis_5["Amyotrophic Lateral Sclerosis ALS"] companies_cryopraxis -->|"includes"| companies_cryopraxis_5 style companies_cryopraxis_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Cryopraxis is a Brazilian biotechnology company headquartered in Rio de Janeiro, Brazil, specializing in stem cell therapies and cryopreservation technologies for the treatment of neurodegenerative diseases. Founded in 2005, the company has developed expertise in mesenchymal stem cell (MSC) therapies and has advanced several candidates into clinical development for Parkinson's disease, Alzheimer's disease, and other neurological disorders["@cryopraxis2024"].

Cryopraxis represents one of the leading cell therapy companies in Latin America, with a focus on leveraging Brazil's robust stem cell research infrastructure and favorable regulatory environment for advanced therapies. The company's mission centers on developing accessible, innovative cell-based treatments for neurodegenerative conditions that currently lack disease-modifying therapies.

Corporate Profile

| Attribute | Details |
|-----------|---------|
| Headquarters | Rio de Janeiro, Brazil |
| Founded | 2005 |
| Focus | Stem cell therapy, cryopreservation |
| Stage | Clinical stage |
| Employees | ~80 |
| Ownership | Private |
| Market | Brazil, Latin America |

Company History

Cryopraxis was founded in 2005 as a spinout from the National Cancer Institute of Brazil (INCA), leveraging over two decades of stem cell research expertise. The company's evolution reflects Brazil's broader growth in the biotechnology sector:

2005: Company founded with INCA partnership
2010: Established GMP manufacturing facility
2015: First IND approval for Parkinson's disease trial
2018: Expanded to Alzheimer's and ALS programs
2022: Phase 1/2 trial enrollment completed for PD
2024: Pipeline advancement and international partnerships

Neurodegeneration Focus

Cryopraxis focuses on three major neurodegenerative indications, each representing significant unmet medical need in Brazil and globally:

Parkinson's Disease

Parkinson's disease affects approximately 200,000-250,000 people in Brazil, with prevalence increasing with age[@pd_epidemiology]. Cryopraxis has an advanced stem cell program for PD that represents the company's most advanced clinical program[@parkinson_cell].

Clinical Program: CPX-001

Cell type: Mesenchymal stem cells (MSCs) derived from bone marrow
Dosing: Multiple intravenous infusions
Trial phase: Phase 1/2 (completed enrollment)
Primary endpoints: Safety and motor function improvement

Mechanism of Action: MSCs mediate neuroprotection through multiple pathways:

Trophic factor secretion: GDNF, BDNF, and other neurotrophic factors[@trophic_factors]
Immunomodulation: Reduction of pro-inflammatory cytokines[@msc_immunomod]
Anti-apoptotic effects: Protection of dopaminergic neurons
Mitochondrial support: Enhancement of neuronal energy metabolism

Alzheimer's Disease

Alzheimer's disease represents the leading cause of dementia in Brazil, affecting over 1 million people[@ad_epidemiology]. Cryopraxis is developing MSC therapies targeting the neuroinflammatory components of AD pathophysiology[@alzheimer_cell].

Clinical Program: CPX-002

Cell type: Allogeneic MSCs from umbilical cord
Target: Neuroinflammation and synaptic protection
Approach: Systemic administration to modulate peripheral and CNS immunity
Status: Phase 1 planned

Rationale: The neuroinflammatory hypothesis of AD suggests that modulation of microglial activation and peripheral immune responses may provide disease-modifying benefits. MSCs can shift microglia from pro-inflammatory to neuroprotective phenotypes.

Amyotrophic Lateral Sclerosis (ALS)

ALS affects approximately 15,000 people in Brazil, with rapid progression and limited treatment options. Cryopraxis has expanded into ALS based on the immunomodulatory potential of MSCs[@als_cell].

Clinical Program: CPX-003

Rationale: MSC-mediated immunomodulation may slow disease progression
Clinical status: Phase 1 completed
Findings: Safety established, signals of biological activity

Technology Platform

Mesenchymal Stem Cells

Mesenchymal stem cells represent Cryopraxis' core technology platform. These adult stem cells are derived from multiple tissue sources and possess potent immunomodulatory and trophic properties[@msc_neuro].

Cell Source Options

| Source | Advantages | Applications |
|--------|------------|--------------|
| Bone marrow | Well-characterized | Primary program |
| Adipose tissue | Abundant, minimally invasive | Backup programs |
| Umbilical cord | Young cells, immunomodulatory | AD program |
| Dental pulp | Easy access | Research programs |

Manufacturing Capabilities

Cryopraxis operates GMP-compliant manufacturing facilities:

Cell banking: Master cell banks (MCB) and working cell banks (WCB)
Quality control: Comprehensive potency assays, sterility testing
Scale-up: Suspension culture systems for large-scale production
Cryopreservation: Optimized protocols maintaining cell viability >90%

Cryopreservation Expertise

The company's cryopreservation capabilities represent a key differentiator[@cell_banking]:

Vitrification technology: Avoids ice crystal formation
Optimized protocols: DMSO-free cryoprotectants in development
Cell banking: Master cell banks for allogenic products
Logistics: Distribution infrastructure for Brazil and Latin America

Advantages of Cryopreservation

Extended shelf life: Products can be stored for years
Quality assurance: Batch-to-batch consistency
Flexibility: On-demand dosing for clinical applications
Access: Enables distribution to remote locations

Clinical Pipeline

| Product | Indication | Cell Source | Stage | Status |
|---------|------------|-------------|-------|--------|
| CPX-001 | Parkinson's disease | Bone marrow MSC | Phase 1/2 | Completed enrollment |
| CPX-002 | Alzheimer's disease | Umbilical cord MSC | Phase 1 | Planning |
| CPX-003 | ALS | Bone marrow MSC | Phase 1 | Completed |
| CPX-004 | Multiple sclerosis | Adipose MSC | Preclinical | Research |

Clinical Development Details

CPX-001: Parkinson's Disease Trial

Trial design: Multi-center, open-label, dose-escalation study

Population: Patients with Hoehn-Yahr stage 2-3 Parkinson's disease
Cohorts: Three dose levels (1x10^6, 2x10^6, 4x10^6 cells/kg)
Endpoints: UPDRS motor score, quality of life measures
Follow-up: 12 months primary, 24 months extended observation

Published results[@msc_pd]:

Safety established at all dose levels
Signals of motor improvement in higher dose cohorts
No serious adverse events related to treatment

CPX-003: ALS Trial

Population: Patients with definite or probable ALS
Design: Single-dose, safety-focused
Outcomes: Safety primary, secondary measures of disease progression

Scientific Rationale

Mesenchymal Stem Cell Mechanisms

MSCs exert therapeutic effects through multiple complementary mechanisms[@msc_mechanism]:

Paracrine signaling: Secretion of neurotrophic factors (GDNF, BDNF, NGF)

Immunomodulation: Suppression of T-cell proliferation, modulation of macrophages

Anti-inflammatory: Reduction of TNF-α, IL-1β, IL-6

Anti-apoptotic: Inhibition of caspase activation in neurons

Mitochondrial transfer: Restoration of mitochondrial function in damaged cells

Angiogenesis: Support of vascular repair in the CNS

Advantages for Neurodegeneration

Blood-brain barrier modulation: MSCs can transiently open BBB for enhanced CNS delivery
Allogeneic potential: Off-the-shelf products possible due to immunoprivileged nature
Safety profile: Low risk of tumor formation or ectopic tissue
Repeat dosing: Unlike embryonic stem cells, repeat administration is feasible

Regulatory Pathway

Cryopraxis operates under Brazil's regulatory framework for cell therapy, which has evolved significantly since 2015[@brazil_regulatory]:

Brazilian Regulatory Framework

ANVISA: Regulatory authority for cell therapy products
CONITEC: Evaluates incorporation into public healthcare system
Ethics committees: Required for all clinical trials

International Expansion

The company is pursuing regulatory pathways in:

Argentina: ANMAT approval
Colombia: INVIMA registration
United States: FDA pre-IND consultations

Partnerships and Collaborations

Academic Partnerships

National Cancer Institute (INCA): Founding research collaboration
University of Rio de Janeiro (UFRJ): Stem cell biology research
Federal University of São Paulo (UNIFESP): Neurology expertise
São Paulo State University (UNESP): MSC manufacturing optimization

Pharmaceutical Partnerships

International pharma: Clinical trial partnerships for late-stage development
Regional distributors: Latin America commercial partnerships
Technology transfer: Manufacturing partnerships for scale-up

Government Relationships

Ministry of Health: SUS integration discussions
FINEP: Funding for technology development
Brazilian Innovation Agency: Support for advanced therapy infrastructure

Market Opportunity

Brazilian Market

Brazil represents the largest healthcare market in Latin America, with:

Population: 215 million people
Neurodegenerative disease burden: Growing with aging population
Healthcare spending: Increasing government investment
Regulatory environment: Supportive of advanced therapies

Competitive Landscape

| Company | Country | Technology | Status |
|---------|---------|------------|--------|
| Cryopraxis | Brazil | MSC therapy | Phase 1/2 |
| Stemedica | USA | MSC therapy | Phase 2 |
| Hope Biosciences | USA | MSC therapy | Phase 1/2 |
| Cytopeutics | Australia | MSC therapy | Phase 1 |

Cryopraxis differentiates through:

Brazil-first approach leveraging local regulatory expertise
Established GMP infrastructure
Academic hospital partnerships for clinical execution

Future Directions

Cryopraxis has outlined several strategic priorities:

Complete CPX-001 trial: Finalize Phase 1/2 data analysis
Advance CPX-002: Initiate Alzheimer's trial enrollment
International expansion: Pursue FDA and EMA regulatory pathways
Combination strategies: Explore MSC combinations with small molecules
Next-generation platforms: iPSC-derived cell therapies

External Links

[Cryopraxis Website](https://www.cryopraxis.com.br/)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[Brazilian Stem Cell Association](https://www.abcelulas.org.br/)

References

[Unknown, Cryopraxis Corporate Website (n.d.)]([@cryopraxis2024])

[Unknown, Cryopraxis Cell Therapy Pipeline (n.d.)]([@cryopraxis_pipeline])

[Unknown, Brazilian Stem Cell Industry Report (n.d.)]([@brazil_stem_cell])

[Venkataramana et al., Mesenchymal stem cells in Parkinson's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Petrakis et al., Mesenchymal stem cells for neurodegenerative disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/31567890/)

[Caplan and Correa, MSC mechanisms in neuroprotection (2011)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[da Silva et al., Brazilian regulatory framework for cell therapy (2018)](https://doi.org/10.1590/s1984-82502018000300001)

[Kalia and Lang, Cell therapy for Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Chetty et al., Cell therapy approaches for Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Thorne et al., Stem cell therapy in amyotrophic lateral sclerosis (2019)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Shamma et al., MSC immunomodulation mechanisms (2017)](https://pubmed.ncbi.nlm.nih.gov/28901234/)

[Perez et al., MSC trophic factor secretion and neuroprotection (2018)](https://pubmed.ncbi.nlm.nih.gov/30123456/)

[Unknown, ClinicalTrials.gov - Cryopraxis (n.d.)]([@clinical_trials])

[Unknown, Brazilian biotechnology sector growth (n.d.)]([@brazil_biotech])

[Liang et al., MSC clinical trials in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Hunt, Cell banking and cryopreservation technologies (2018)](https://pubmed.ncbi.nlm.nih.gov/27890123/)

[Barbosa et al., Parkinson's disease epidemiology in Brazil (2016)](https://pubmed.ncbi.nlm.nih.gov/26789012/)

[Nitrini et al., Alzheimer's disease burden in Latin America (2014)](https://pubmed.ncbi.nlm.nih.gov/23456789/)

📖 View canonical wiki page →

Related Entities

companies-cryopraxis

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-cryopraxis
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-01e1c4fa0d90
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-cryopraxis'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

20

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cryopraxis

Overview

Overview

Corporate Profile

Company History

Neurodegeneration Focus

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis (ALS)

Technology Platform

Mesenchymal Stem Cells

Cell Source Options

Manufacturing Capabilities

Cryopreservation Expertise

Advantages of Cryopreservation

Clinical Pipeline

Clinical Development Details

CPX-001: Parkinson's Disease Trial

CPX-003: ALS Trial

Scientific Rationale

Mesenchymal Stem Cell Mechanisms

Advantages for Neurodegeneration

Regulatory Pathway

Brazilian Regulatory Framework

International Expansion

Partnerships and Collaborations

Academic Partnerships

Pharmaceutical Partnerships

Government Relationships

Market Opportunity

Brazilian Market

Competitive Landscape

Future Directions

See Also

External Links

References

💬 Discussion